Skip to content

Research at St Andrews

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

Research output: Contribution to journalArticle

DOI

Author(s)

Patrick P. J. Phillips, Stephen H. Gillespie, Martin Boeree, Norbert Heinrich, Rob Aarnoutse, Tim McHugh, Michel Pletschette, Christian Lienhardt, Richard Hafner, Charles Mgone, Alimuddin Zumla, Andrew J. Nunn, Michael Hoelscher

School/Research organisations

Abstract

A growing number of new drugs for the treatment of tuberculosis are in clinical development. Confirmatory phase 3 trials are expensive and time-consuming and the question of whether one particular drug combination can be used to treat tuberculosis is less important from a public health perspective than the question of which are the shortest, simplest, most effective, and safest regimens. While preclinical and phase 1 studies provide some guidance in the selection of combinations for clinical evaluation, a large number of combinations will require phase 2 testing to ensure that only the best regimens advance to phase 3. The multi-arm multi-stage trial design is an example of a treatment selection-adaptive design where multiple experimental arms are each simultaneously compared with a common control and interim analyses allow for poor performing arms to be dropped early. Such designs, if designed and implemented correctly, require fewer patients, can be completed in a shorter time frame, and answer more relevant questions without any loss in statistical validity or scientific integrity. There are, however, practical issues that must be considered in applying this in tuberculosis treatment trials. More innovative trials designs should be considered to speed drug and regimen development for the treatment of tuberculosis.

Close

Details

Original languageEnglish
Pages (from-to)S250-S257
Number of pages8
JournalJournal of Infectious Diseases
Volume205
DOIs
Publication statusPublished - 15 May 2012

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy.

    Research output: Contribution to journalArticle

  2. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  3. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

  4. Molecular bacterial load assay (MBLA) concurs with culture on the NaOH-induced Mycobacterium tuberculosis loss of viability

    Mtafya, B., Sabiiti, W., Sabi, I., John, J., Sichone, E., Ntinginya, N. E. & Gillespie, S. H., 25 Jun 2019, In : Journal of Clinical Microbiology. 57, e01992-18.

    Research output: Contribution to journalArticle

  5. Heat-inactivation renders sputum safe and preserves Mycobacterium tuberculosis RNA for downstream molecular tests

    Sabiiti, W., Azam, K., Esmeraldo, E., Bhatt, N., Rachow, A. & Gillespie, S. H., Mar 2019, In : Journal of Clinical Microbiology. 57, 4, 8 p., e01778-18.

    Research output: Contribution to journalArticle

Related by journal

  1. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

    Coxon, G., Cooper, C., Gillespie, S. H. & McHugh, T., Mar 2012, Journal of Infectious Diseases, supplement, p. S1-7 8 p.

    Research output: Contribution to specialist publicationArticle

Related by journal

  1. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations

    Svensson, R. J., Svensson, E. M., Aarnoutse, R. E., Diacon, A. H., Dawson, R., Gillespie, S. H., Moodley, M., Boeree, M. J. & Simonsson, U. S. H., 28 Apr 2018, In : Journal of Infectious Diseases. In press

    Research output: Contribution to journalArticle

  2. Fragmented population structure of Plasmodium falciparum in a region of declining endemicity

    Anthony, T. G., Conway, D. J., Cox-Singh, J., Matusop, A., Ratnam, S., Shamsul, S., Singh, B. & Cox Singh, J., 1 May 2005, In : Journal of Infectious Diseases. 191, 9, p. 1558-1564 7 p.

    Research output: Contribution to journalArticle

  3. Iron Regulates Hepatitis C Virus Translation via Stimulation of Expression of Translation Initiation Factor 3

    Theural, I., Zoller, H., Obrist, P., Datz, C., Bachmann, F., Elliott, R. M. & Weiss, G., 15 Aug 2004, In : Journal of Infectious Diseases. 190, 4, p. 819-825 7 p.

    Research output: Contribution to journalArticle

ID: 22449921